Medical Devices & Tech

Vessix Vascular (Formerly Minnow Medical)

26052 Merit Circle, Suite 106
Laguna Hills, CA 92653 USA
Click for website

Research Sector Medical Devices & Tech

Summary Description Catheter-based Energy Treatment for Peripheral Artery Disease, including in-stent restenosis and DVT.

Management Raymond W. Cohen, Chief Executive Officer Prabodh Mathur, Chief Product Development Officer Sharon Riddle, Vice President of Market Development; Mike Handley, VP, Clinical and Regulatory Affairs Dan Dearen, Chief Financial Officer; Olav Bergheim, Chairman

Click here for Financial Data
Keywords: cardiovascular disease, artery disease, catheter technology, peripheral artery disease, in-stent restenosis, DVT


Updated: Aug. 22, 2013


Vessix Vascular, Inc. continues to expand the endovascular clinical applications for its patented low-pressure percutaneous transluminal angioplasty catheter mounted with RF electrodes. The Company......view more

Products / Services

Through collaboration with leading physicians, researchers and scientists, Minnow Medical has developed its initial product, the ZCath Peripheral Vascular System. The ZCath combines a patented low-......view more

Technology / Differentiation

Established peripheral artery procedures utilize a wide range of technologies from surgical by-pass to endovascular treatments such as angioplasty, stenting, laser, and atherectomy therapy. These ther...view more

Market / Customers

In-Stent Restenosis (ISR) in the peripheral arteries is Minnows primary target market. Historically, arterial disease in the superficial femoral artery (SFA) has been treated with bypass surger......view more

Competitors / Substitutes / Alternatives

Current catheter-based treatments for artery disease include; plain old balloon angioplasty, laser, cryoplasty and atherectomy....view more


Establish clinical efficacy for various clinical indications and partner with large established players to license and distribute our products....view more

Revenue / Funding

We are seeking $7 to $10 million in new capital to complete our European study for ISR which is scheduled to begin in late Q1 2011 and to conduct a clinical study in the U.S. Proceeds from the financi...view more


Minnow has already treated over 80 patients in Europe, has a CE Mark for its ZCath System and a 510(k) pending with the FDA for its initial indication. The Company is planning a new study to treat pat...view more